Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination ...
Luveltamab tazevibulin (luvelta) + bevacizumab showed 56% ORR in late-stage ovarian cancer at RP2D, with 35% overall response rate. No new safety signals were observed. Expansion at RP2D ongoing with 23 additional patients enrolled; data expected in H1 2025.
Highlighted Terms
Related News
Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination ...
Luveltamab tazevibulin (luvelta) + bevacizumab showed 56% ORR in late-stage ovarian cancer at RP2D, with 35% overall response rate. No new safety signals were observed. Expansion at RP2D ongoing with 23 additional patients enrolled; data expected in H1 2025.